JP7402807B2 - グリピカン３抗体およびそのコンジュゲート - Google Patents

グリピカン３抗体およびそのコンジュゲート Download PDF

Info

Publication number
JP7402807B2
JP7402807B2 JP2020543351A JP2020543351A JP7402807B2 JP 7402807 B2 JP7402807 B2 JP 7402807B2 JP 2020543351 A JP2020543351 A JP 2020543351A JP 2020543351 A JP2020543351 A JP 2020543351A JP 7402807 B2 JP7402807 B2 JP 7402807B2
Authority
JP
Japan
Prior art keywords
antibody
occupied
drug conjugate
drug
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513844A5 (https=
JP2021513844A (ja
JPWO2019161174A5 (https=
Inventor
トラヴィス ビシェレ，
ウィリアム アーサー，
パトリック バーク，
ローリ ウエステンドルフ，
Original Assignee
シージェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージェン インコーポレイテッド filed Critical シージェン インコーポレイテッド
Publication of JP2021513844A publication Critical patent/JP2021513844A/ja
Publication of JP2021513844A5 publication Critical patent/JP2021513844A5/ja
Publication of JPWO2019161174A5 publication Critical patent/JPWO2019161174A5/ja
Priority to JP2023067166A priority Critical patent/JP2023089195A/ja
Application granted granted Critical
Publication of JP7402807B2 publication Critical patent/JP7402807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020543351A 2018-02-15 2019-02-15 グリピカン３抗体およびそのコンジュゲート Active JP7402807B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023067166A JP2023089195A (ja) 2018-02-15 2023-04-17 グリピカン３抗体およびそのコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862631353P 2018-02-15 2018-02-15
US62/631,353 2018-02-15
PCT/US2019/018182 WO2019161174A1 (en) 2018-02-15 2019-02-15 Glypican 3 antibodies and conjugates thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023067166A Division JP2023089195A (ja) 2018-02-15 2023-04-17 グリピカン３抗体およびそのコンジュゲート

Publications (4)

Publication Number Publication Date
JP2021513844A JP2021513844A (ja) 2021-06-03
JP2021513844A5 JP2021513844A5 (https=) 2022-02-22
JPWO2019161174A5 JPWO2019161174A5 (https=) 2022-02-22
JP7402807B2 true JP7402807B2 (ja) 2023-12-21

Family

ID=67620075

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543351A Active JP7402807B2 (ja) 2018-02-15 2019-02-15 グリピカン３抗体およびそのコンジュゲート
JP2023067166A Pending JP2023089195A (ja) 2018-02-15 2023-04-17 グリピカン３抗体およびそのコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023067166A Pending JP2023089195A (ja) 2018-02-15 2023-04-17 グリピカン３抗体およびそのコンジュゲート

Country Status (13)

Country Link
US (2) US11819553B2 (https=)
EP (1) EP3752534A4 (https=)
JP (2) JP7402807B2 (https=)
KR (1) KR20200121317A (https=)
CN (1) CN111712520A (https=)
AR (1) AR114112A1 (https=)
AU (1) AU2019220700A1 (https=)
CA (1) CA3090251A1 (https=)
IL (1) IL276514B2 (https=)
MX (1) MX2020008030A (https=)
SG (1) SG11202007073SA (https=)
TW (1) TWI851552B (https=)
WO (1) WO2019161174A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
CA3170023A1 (en) * 2020-02-27 2021-09-02 Nanjing Legend Biotech Co., Ltd. Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
WO2021207701A1 (en) 2020-04-10 2021-10-14 Seagen Inc. Charge variant linkers
EP4146702A4 (en) * 2020-05-07 2024-07-10 Phanes Therapeutics, Inc. Anti-tumor associated antigen antibodies and uses thereof
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN112921005B (zh) * 2021-04-14 2023-07-07 中国农业科学院兰州兽医研究所 一株杂交瘤细胞株及其产生的犬细小病毒vp2蛋白单克隆抗体和应用
CA3221398A1 (en) 2021-05-28 2022-12-01 Seagen Inc. Anthracycline antibody conjugates
IL310866A (en) * 2021-08-19 2024-04-01 Adicet Therapeutics Inc Methods for the detection of membrane-bound glypican-3
WO2023045151A1 (en) * 2021-09-24 2023-03-30 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against gpc3 and uses thereof
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
WO2023207475A1 (zh) * 2022-04-24 2023-11-02 昱言科技(北京)有限公司 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物
CN119894536A (zh) * 2022-09-22 2025-04-25 乐普生物科技股份有限公司 Gpc3抗体药物偶联物及其应用
CN119968398A (zh) * 2022-11-28 2025-05-09 四川科伦博泰生物医药股份有限公司 靶向gpc3的抗体及其用途
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
CN119424671A (zh) * 2023-08-01 2025-02-14 上海新理念生物医药科技有限公司 含糖基吡啶型连接子的抗体药物偶联物
WO2025090774A1 (en) 2023-10-24 2025-05-01 Seagen Inc. Chemotherapeutic compounds and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232848A (ja) 2004-07-09 2009-10-15 Chugai Pharmaceut Co Ltd 抗グリピカン３抗体
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
JP2017530100A (ja) 2014-09-11 2017-10-12 シアトル ジェネティックス， インコーポレイテッド 第３級アミン含有薬物物質の標的送達
WO2017181109A1 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
JP2017532048A (ja) 2014-07-02 2017-11-02 カリプソ バイオテク エス アーＣａｌｙｐｓｏ Ｂｉｏｔｅｃｈ Ｓａ Ｉｌ−１５に対する抗体
US20170326249A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
CA2451493C (en) 2001-06-22 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Cell growth inhibitors containing anti-glypican 3 antibody
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
BR112012012912A2 (pt) 2009-11-30 2016-10-25 Biotest Ag anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
CN113933504A (zh) * 2014-05-08 2022-01-14 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232848A (ja) 2004-07-09 2009-10-15 Chugai Pharmaceut Co Ltd 抗グリピカン３抗体
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
JP2017532048A (ja) 2014-07-02 2017-11-02 カリプソ バイオテク エス アーＣａｌｙｐｓｏ Ｂｉｏｔｅｃｈ Ｓａ Ｉｌ−１５に対する抗体
JP2017530100A (ja) 2014-09-11 2017-10-12 シアトル ジェネティックス， インコーポレイテッド 第３級アミン含有薬物物質の標的送達
WO2017181109A1 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
US20170326249A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses

Also Published As

Publication number Publication date
CA3090251A1 (en) 2019-08-22
IL276514B2 (en) 2024-12-01
US20240173427A1 (en) 2024-05-30
TWI851552B (zh) 2024-08-11
AU2019220700A1 (en) 2020-09-24
TW201938587A (zh) 2019-10-01
SG11202007073SA (en) 2020-08-28
US20210361776A1 (en) 2021-11-25
JP2021513844A (ja) 2021-06-03
CN111712520A (zh) 2020-09-25
US11819553B2 (en) 2023-11-21
IL276514A (en) 2020-09-30
AR114112A1 (es) 2020-07-22
JP2023089195A (ja) 2023-06-27
IL276514B1 (en) 2024-08-01
EP3752534A1 (en) 2020-12-23
MX2020008030A (es) 2020-09-10
KR20200121317A (ko) 2020-10-23
WO2019161174A1 (en) 2019-08-22
EP3752534A4 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP7402807B2 (ja) グリピカン３抗体およびそのコンジュゲート
EP3307274B1 (en) Anti-cd123 antibodies and conjugates thereof
JP7718816B2 (ja) 抗メソセリン抗体およびその抗体薬物コンジュゲート
JP2024096335A (ja) 親水性抗体－薬物コンジュゲート
JP6892826B2 (ja) Ｃｄ４８抗体及びその複合体
KR20240082348A (ko) 항체, 이의 항체-약물 접합체 및 이의 용도
JP2026026483A (ja) 標的化デンドリマー複合体
KR20180021177A (ko) 항-cd123 항체 및 이들의 접합체와 유도체
JP2021505676A (ja) 抗ｃｄ２２抗体−メイタンシンコンジュゲートおよびその使用方法
JP2023529640A (ja) 治療用コンジュゲート
IL259186B2 (en) Anti-cd22-maytensin antibody conjugates and methods of using them
JP7203834B2 (ja) イムノコンジュゲートにおけるメチオニン酸化を防止する方法
HK1253305B (en) Anti-cd123 antibodies and conjugates thereof
HK1248538B (zh) Cd48抗体和其缀合物
BR112014028507B1 (pt) Anticorpos cd33 e uso dos mesmos para tratar câncer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231211

R150 Certificate of patent or registration of utility model

Ref document number: 7402807

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150